Document is current
Any future updates will be listed below
-
Authors
Fiskus, Warren https://orcid.org/0000-0002-7343-6214
Daver, Naval https://orcid.org/0000-0001-7103-373X
Boettcher, Steffen https://orcid.org/0000-0001-9937-0957
Mill, Christopher P.
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Birdwell, Christine E.
Davis, John A.
Das, Kaberi https://orcid.org/0000-0003-4702-0386
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Burrows, Francis
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Khoury, Joseph D. https://orcid.org/0000-0003-2621-3584
Ebert, Benjamin L. https://orcid.org/0000-0003-0197-5451
Bhalla, Kapil N. https://orcid.org/0000-0001-5209-5126
- License Information
-
More Information
Article History
Received: 12 July 2022
Revised: 8 September 2022
Accepted: 9 September 2022
First Online: 23 September 2022
Competing interests
: FB is an employee of Kura Oncology, Inc. BLE has received research funding from Celgene, Deerfield, Novartis, and Calico; and he is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, Skyhawk Therapeutics, and Exo Therapeutics, none of which are directly related to the content of this paper. All other authors declare they have no financial interests to disclose.
